X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT LTD. GLENMARK PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 14.4 -18.7 - View Chart
P/BV x 3.8 3.1 124.1% View Chart
Dividend Yield % 0.3 1.1 29.5%  

Financials

 GLENMARK PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
WOCKHARDT LTD.
Mar-17
GLENMARK PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs9931,129 88.0%   
Low Rs729627 116.3%   
Sales per share (Unadj.) Rs325.5363.1 89.6%  
Earnings per share (Unadj.) Rs39.3-20.4 -192.2%  
Cash flow per share (Unadj.) Rs48.7-7.0 -697.7%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.1 20.4%  
Book value per share (Unadj.) Rs159.2301.8 52.7%  
Shares outstanding (eoy) m282.17110.55 255.2%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.62.4 109.4%   
Avg P/E ratio x21.9-42.9 -51.0%  
P/CF ratio (eoy) x17.7-125.9 -14.1%  
Price / Book Value ratio x5.42.9 185.9%  
Dividend payout %5.1-48.9 -10.4%   
Avg Mkt Cap Rs m242,99197,063 250.3%   
No. of employees `00013.06.8 191.6%   
Total wages/salary Rs m16,4089,665 169.8%   
Avg. sales/employee Rs Th7,083.95,931.8 119.4%   
Avg. wages/employee Rs Th1,265.41,428.1 88.6%   
Avg. net profit/employee Rs Th855.1-334.0 -256.0%   
INCOME DATA
Net Sales Rs m91,85740,146 228.8%  
Other income Rs m3741,143 32.7%   
Total revenues Rs m92,23041,289 223.4%   
Gross profit Rs m20,367128 15,911.8%  
Depreciation Rs m2,6441,489 177.5%   
Interest Rs m2,3732,253 105.3%   
Profit before tax Rs m15,724-2,472 -636.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827-211 -1,812.8%   
Profit after tax Rs m11,088-2,260 -490.5%  
Gross profit margin %22.20.3 6,954.2%  
Effective tax rate %24.38.5 284.9%   
Net profit margin %12.1-5.6 -214.4%  
BALANCE SHEET DATA
Current assets Rs m68,74646,160 148.9%   
Current liabilities Rs m27,02719,258 140.3%   
Net working cap to sales %45.467.0 67.8%  
Current ratio x2.52.4 106.1%  
Inventory Days Days85101 84.4%  
Debtors Days Days9694 101.6%  
Net fixed assets Rs m24,13240,165 60.1%   
Share capital Rs m282553 51.1%   
"Free" reserves Rs m44,64332,814 136.0%   
Net worth Rs m44,92533,367 134.6%   
Long term debt Rs m45,36331,903 142.2%   
Total assets Rs m117,63989,687 131.2%  
Interest coverage x7.6-0.1 -7,851.1%   
Debt to equity ratio x1.01.0 105.6%  
Sales to assets ratio x0.80.4 174.4%   
Return on assets %11.40 -133,277.2%  
Return on equity %24.7-6.8 -364.3%  
Return on capital %19.1-0.3 -5,711.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,1529,121 615.6%   
Fx outflow Rs m8,0842,133 379.0%   
Net fx Rs m48,0686,988 687.9%   
CASH FLOW
From Operations Rs m6,574-2,695 -244.0%  
From Investments Rs m-7,124-6,863 103.8%  
From Financial Activity Rs m5,43212,545 43.3%  
Net Cashflow Rs m1,9923,010 66.2%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  SUVEN LIFE  DR. DATSONS LABS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - NOVARTIS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS